Skip to main content
x

Recent articles

Dizal's US first; now what?

Zegfrovy is approved in a best-case setting, but Dizal has no US presence.

FDA red and green lights: June 2025

Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.

The month ahead: July’s upcoming events

Regeneron is facing two FDA decisions for its T-cell engagers.

BeOne tries to repeat the inhibitor-degrader double

Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.

BeOne also needs B7-H4 biomarkers

The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.

Amgen and Zai Lab eye a gastric niche

Adverse events will be closely watched when full data are reported.